SRR8518383
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.540
- OXIDATIVE_PHOSPHORYLATION+0.540
- MYC_TARGETS_V2+0.470
- PANCREAS_BETA_CELLS+0.360
- PROTEIN_SECRETION+0.360
- MTORC1_SIGNALING+0.340
- E2F_TARGETS+0.310
- GLYCOLYSIS+0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- ADIPOGENESIS+0.230
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.490
- INTERFERON_ALPHA_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.470
- TNFA_SIGNALING_VIA_NFKB-0.450
- INFLAMMATORY_RESPONSE-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- ALLOGRAFT_REJECTION-0.330
- UV_RESPONSE_DN-0.330
- COMPLEMENT-0.310
- IL2_STAT5_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-4582-01A-01R-1443-07 | — | cohortSQ2 | 0.924 |
| 2 | TCGA-DK-AA71-01A-31R-A39I-07 | — | — | 0.895 |
| 3 | TCGA-66-2766-01A-01R-0851-07 | — | cohortSQ2 | 0.883 |
| 4 | sclcM1220157A_S67.txt | — | cohortSC | 0.883 |
| 5 | SRR2016943 | — | — | 0.880 |
| 6 | DRR168541 | — | — | 0.879 |
| 7 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.874 |
| 8 | s0112311 | — | — | 0.874 |
| 9 | TCGA-CN-4730-01A-01R-1436-07 | — | — | 0.874 |
| 10 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |